openFDA FAERS liver adverse-event slices for MASLD drugs (resmetirom/pioglitazone/OCA/semaglutide/vit-E)

Accession: openFDA-FAERS-MASLD-drugs-liver-AEs
Source / host: openFDA — openFDA (api.fda.gov)
Disease relevance: MASLD / NAFLD / NASH (category: Safety-tox, subtype: FAERS adverse events (liver-scoped))
Modality / assay: pharmacovigilance
Platform: openFDA drug/event
Organism: human
Samples: 0
Size (indexed): 26.3 KB (26931 bytes)
Access / raw: public / OPEN-processed

Download

Files

FileSizeSHA256
faers_resmetirom_liver_reactions.json1.6 KB016729ddb83af447…
faers_pioglitazone_liver_reactions.json148 Bac4b151563a7b8aa…
faers_obeticholic_acid_liver_reactions.json403 Baccd5a56ebfb8d00…
faers_semaglutide_liver_reactions.json433 Be38e0c11dfa94bac…
faers_vitamin_e_liver_reactions.json385 B2e656819e8849b45…
faers_MASLD_drugs_combined.json23.3 KBaa43473de0c96759…

Index note: openFDA FAERS liver-scoped reaction slices for 5 MASLD drugs

Crawled by masld-atlas-crawler v1.0 at 2026-08-06T03:39:37Z.

About this dataset

This openFDA drug/event dataset provides single-cell gene expression from human liver samples, with disease state recorded as MASLD/NAFLD/NASH.

Analyze it in Drylab

Open this dataset in Drylab and ask a question in plain language. The AI agent loads the files, runs the analysis in a ready sandbox and explains each result. A typical first pass:

  1. Load the filtered feature-barcode matrix (HDF5) and run quality control on counts, genes and mitochondrial reads per cell.
  2. Normalize, select variable genes, then cluster the cells and draw a UMAP.
  3. Annotate clusters with marker genes and compare the cell-type mix between conditions.
  4. Run differential expression between cell types or samples to characterize masld/nafld/nash biology.